March 2018 - Page 22 of 48 - NetworkNewsWire

TuesdayMar 13, 2018 10:00 am

iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN) Starts Presentation at 30th Annual ROTH Conference

iAnthus Capital Holdings (OTCQB: ITHUF) owns and operates licensed cannabis cultivation, processing and dispensary facilities throughout the United States, providing investors diversified exposure to licensed cannabis cultivators, processors and dispensaries throughout the United States. Founded by entrepreneurs with decades of experience in operations, investment banking, corporate finance, law and healthcare services, iAnthus provides a combination of capital and hands-on operating and management expertise. The company harnesses these skills to support operations across six states. For more information, visit the company’s website at www.iAnthuscapital.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to…

MondayMar 12, 2018 8:30 pm

Hemispherx Biopharma, Inc. (NYSE: HEB) Starts Presentation at 30th Annual ROTH Conference

Hemispherx Biopharma (NYSE: HEB) is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutic rintatolimod. Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life-threatening diseases. For more information, visit the company’s website at www.hemispherx.net. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that…

MondayMar 12, 2018 8:30 pm

CTi BioPharma Corp. (NASDAQ: CTIC) Starts Presentation at 30th Annual ROTH Conference

CTI BioPharma (NASDAQ: CTIC) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. For more information, visit the company’s website at www.ctibiopharma.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and…

MondayMar 12, 2018 8:30 pm

Willdan Group, Inc. (NASDAQ: WLDN) Starts Presentation at 30th Annual ROTH Conference

Willdan Group (NASDAQ: WLDN) is a provider of professional consulting and technical services to utilities, public agencies and private industry throughout the United States. The company's services span a broad set of complementary disciplines that include energy efficiency and sustainability, engineering and planning, financial and economic consulting, and national preparedness. Willdan offers integrated technical solutions to extend the reach and resources of its clients, providing all services through subsidiaries that specialize in each segment. For more information, visit the company’s website at www.willdan.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to…

MondayMar 12, 2018 8:30 pm

OPTIMIZERx Corp. (OPRX) Starts Presentation at 30th Annual ROTH Conference

OptimizeRx® (OTC:OPRX) is the nation’s leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company’s cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information. The company’s network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more than half a million healthcare providers access to these benefits within their workflow at the point of care. For more information, visit the company’s website at www.optimizerx.com. About NetworkNewsWire NetworkNewsWire (NNW)…

MondayMar 12, 2018 8:30 pm

SuperCom Ltd. (NASDAQ: SPCB) Starts Presentation at 30th Annual ROTH Conference

SuperCom (NASDAQ: SPCB) has been a global provider of traditional and digital identity solutions since 1988, offering advanced safety, identification and security solutions to governments and both private and public organizations across the globe. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, the company has inspired governments and national agencies to design and issue secure multi-ID documents and strong digital identity solutions to citizens and visitors. SuperCom offers a distinctive, field-proven all-in-one identification, tracking and monitoring IoT hybrid suite along with cyber security products, a secured payments platform and…

MondayMar 12, 2018 8:30 pm

miRagen Therapeutics, Inc. (NASDAQ: MGEN) Starts Presentation at 30th Annual ROTH Conference

miRagen Therapeutics (NASDAQ: MGEN) is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs. The company’s MRG-106 is a clinical product candidate for the treatment of certain cancers. miRagen’s clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as systemic sclerosis. The company is also developing MRG-110 for the treatment of heart failure and other ischemic disease. miRagen’s translational medicine strategy is…

MondayMar 12, 2018 8:00 pm

Jason Industries, Inc. (NASDAQ: JASN) Starts Presentation at 30th Annual ROTH Conference

Jason Industries (NASDAQ: JASN) is a globally diversified company comprised of four distinct manufacturing businesses that enhance end user’s comfort, safety and productivity. The company delivers finishing, components, seating and acoustics products and solutions to industrial, energy, heavy fabrication, off-highway equipment and transportation markets in the United States and internationally. Jason Industries is the parent company to a global family of manufacturers including Osborn, Metalex, Milsco, and Janesville Acoustics. Headquartered in Milwaukee, Wisconsin, Jason employs more than 4,200 people in 13 countries. For more information, visit the company’s website at www.jasoninc.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news and…

MondayMar 12, 2018 8:00 pm

EnSync, Inc. (NYSE: ESNC) Starts Presentation at 30th Annual ROTH Conference

EnSync (NYSE: ESNC) is creating innovative distributed energy resource (“DER”) systems and Internet of energy (“IOE”) control platforms. The company uses an electrical infrastructure that prioritizes the use of all available resources, such as renewables, energy storage and the utility grid. As project developer, the company provides load analysis, system design consulting, and technical and financial modeling to ensure energy systems are sized and optimized to meet customers’ objectives. EnSync Energy’s IOE control platform adapts easily to ever-changing generation and load variables, as well as changes in utility prices and programs, ensuring the means to make or save money behind-the-meter,…

MondayMar 12, 2018 8:00 pm

ArQule, Inc. (NASDAQ: ARQL) Starts Presentation at 30th Annual ROTH Conference

ArQule (NASDAQ: ARQL) is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. The company’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need to significantly extend and improve the lives of patients. The company’s clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations. The company’s proprietary pipeline includes Derazantinib, Miransertib (ARQ 092), ARQ 751 and ARQ 761. Additionally, ArQule has advanced ARQ 531 to phase 1 for patients with B-cell malignancies refractory to other therapeutic…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Month: March 2018

iAnthus Capital Holdings, Inc. (OTC: ITHUF) (CSE: IAN) Starts Presentation at 30th Annual ROTH Conference

Hemispherx Biopharma, Inc. (NYSE: HEB) Starts Presentation at 30th Annual ROTH Conference

CTi BioPharma Corp. (NASDAQ: CTIC) Starts Presentation at 30th Annual ROTH Conference

Willdan Group, Inc. (NASDAQ: WLDN) Starts Presentation at 30th Annual ROTH Conference

OPTIMIZERx Corp. (OPRX) Starts Presentation at 30th Annual ROTH Conference

SuperCom Ltd. (NASDAQ: SPCB) Starts Presentation at 30th Annual ROTH Conference

miRagen Therapeutics, Inc. (NASDAQ: MGEN) Starts Presentation at 30th Annual ROTH Conference

Jason Industries, Inc. (NASDAQ: JASN) Starts Presentation at 30th Annual ROTH Conference

EnSync, Inc. (NYSE: ESNC) Starts Presentation at 30th Annual ROTH Conference

ArQule, Inc. (NASDAQ: ARQL) Starts Presentation at 30th Annual ROTH Conference

NetworkNewsWire Currently Accepts

NetworkNewsWire

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsWire Currently Accepts

Company Search

Site Search